Could an arthritis drug save lives from a deadly brain infection?
NCT ID NCT05590455
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding adalimumab (an arthritis drug) to standard tuberculosis meningitis treatment can reduce deaths in HIV-positive adults. About 130 participants in Brazil, Mozambique, and Zambia will receive adalimumab injections every two weeks for 10 weeks alongside anti-TB drugs and steroids. The study focuses on survival at three months and monitors for serious infections and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adalimumab (a TNF inhibitor injection)
What this could lead to
If it works, this could point toward a new treatment that lowers the high death rate from tuberculosis meningitis in people with HIV.
What could go wrong
This is a small, early-phase trial (130 participants) testing safety and effectiveness. Adding a strong immune-suppressing drug may increase the risk of serious infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV I INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Adult Infectious Diseases Centre, University Teaching Hospital
NOT_YET_RECRUITINGLusaka, Zambia
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
Instituto Nacional de Saude
NOT_YET_RECRUITINGMaputo, Mozambique
Contact
Contact Email: •••••@•••••
-
Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ
RECRUITINGRio de Janeiro, 21040-900, Brazil
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••